Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma

F. E. Valles, C. L. Perez-Valles, S. Regalado, Ramon Barajas, J. L. Rubenstein, S. Cha

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

BACKGROUNDANDPURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information. MATERIALS AND METHODS: Pretherapy baseline DWI and DSC perfusion MR imaging in 25 patients with PCNSL was analyzed before methotrexate-based induction chemotherapy. Contrast-enhancing tumor was segmented and coregistered with ADC and rCBV maps, and mean and minimum values were measured. Patients were separated into high or low ADC groups on the basis of previously published threshold values of ADCmin-6mm2/s. High and low rCBV groups were defined on the basis of receiver operating curve analysis. High and low ADC and rCBV groups were analyzed independently and in combination. Multivariate Cox survival analysis was performed. RESULTS: Patients with ADCmin values <384 × 10-6 mm2/s or rCBVmean values <1.43 had worse PFS and OS. The patient cohort with combined low ADCmin-low rCBVmean had the worst prognosis. No other variables besides ADC and rCBV significantly affected survival. CONCLUSIONS: Our study reinforces the validity of ADC values as a prognostic biomarker and provides the first evidence of low tumor rCBV as a novel risk factor for adverse prognosis in immunocompetent patients with PCNSL.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalAmerican Journal of Neuroradiology
Volume34
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Perfusion Imaging
Lymphoma
Central Nervous System
Biomarkers
Induction Chemotherapy
Survival Analysis
Methotrexate
Neoplasms
Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. / Valles, F. E.; Perez-Valles, C. L.; Regalado, S.; Barajas, Ramon; Rubenstein, J. L.; Cha, S.

In: American Journal of Neuroradiology, Vol. 34, No. 1, 01.2013, p. 35-40.

Research output: Contribution to journalArticle

@article{3b8bce5ad6784494af7422bb945162ef,
title = "Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma",
abstract = "BACKGROUNDANDPURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information. MATERIALS AND METHODS: Pretherapy baseline DWI and DSC perfusion MR imaging in 25 patients with PCNSL was analyzed before methotrexate-based induction chemotherapy. Contrast-enhancing tumor was segmented and coregistered with ADC and rCBV maps, and mean and minimum values were measured. Patients were separated into high or low ADC groups on the basis of previously published threshold values of ADCmin-6mm2/s. High and low rCBV groups were defined on the basis of receiver operating curve analysis. High and low ADC and rCBV groups were analyzed independently and in combination. Multivariate Cox survival analysis was performed. RESULTS: Patients with ADCmin values <384 × 10-6 mm2/s or rCBVmean values <1.43 had worse PFS and OS. The patient cohort with combined low ADCmin-low rCBVmean had the worst prognosis. No other variables besides ADC and rCBV significantly affected survival. CONCLUSIONS: Our study reinforces the validity of ADC values as a prognostic biomarker and provides the first evidence of low tumor rCBV as a novel risk factor for adverse prognosis in immunocompetent patients with PCNSL.",
author = "Valles, {F. E.} and Perez-Valles, {C. L.} and S. Regalado and Ramon Barajas and Rubenstein, {J. L.} and S. Cha",
year = "2013",
month = "1",
doi = "10.3174/ajnr.A3165",
language = "English (US)",
volume = "34",
pages = "35--40",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "1",

}

TY - JOUR

T1 - Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma

AU - Valles, F. E.

AU - Perez-Valles, C. L.

AU - Regalado, S.

AU - Barajas, Ramon

AU - Rubenstein, J. L.

AU - Cha, S.

PY - 2013/1

Y1 - 2013/1

N2 - BACKGROUNDANDPURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information. MATERIALS AND METHODS: Pretherapy baseline DWI and DSC perfusion MR imaging in 25 patients with PCNSL was analyzed before methotrexate-based induction chemotherapy. Contrast-enhancing tumor was segmented and coregistered with ADC and rCBV maps, and mean and minimum values were measured. Patients were separated into high or low ADC groups on the basis of previously published threshold values of ADCmin-6mm2/s. High and low rCBV groups were defined on the basis of receiver operating curve analysis. High and low ADC and rCBV groups were analyzed independently and in combination. Multivariate Cox survival analysis was performed. RESULTS: Patients with ADCmin values <384 × 10-6 mm2/s or rCBVmean values <1.43 had worse PFS and OS. The patient cohort with combined low ADCmin-low rCBVmean had the worst prognosis. No other variables besides ADC and rCBV significantly affected survival. CONCLUSIONS: Our study reinforces the validity of ADC values as a prognostic biomarker and provides the first evidence of low tumor rCBV as a novel risk factor for adverse prognosis in immunocompetent patients with PCNSL.

AB - BACKGROUNDANDPURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information. MATERIALS AND METHODS: Pretherapy baseline DWI and DSC perfusion MR imaging in 25 patients with PCNSL was analyzed before methotrexate-based induction chemotherapy. Contrast-enhancing tumor was segmented and coregistered with ADC and rCBV maps, and mean and minimum values were measured. Patients were separated into high or low ADC groups on the basis of previously published threshold values of ADCmin-6mm2/s. High and low rCBV groups were defined on the basis of receiver operating curve analysis. High and low ADC and rCBV groups were analyzed independently and in combination. Multivariate Cox survival analysis was performed. RESULTS: Patients with ADCmin values <384 × 10-6 mm2/s or rCBVmean values <1.43 had worse PFS and OS. The patient cohort with combined low ADCmin-low rCBVmean had the worst prognosis. No other variables besides ADC and rCBV significantly affected survival. CONCLUSIONS: Our study reinforces the validity of ADC values as a prognostic biomarker and provides the first evidence of low tumor rCBV as a novel risk factor for adverse prognosis in immunocompetent patients with PCNSL.

UR - http://www.scopus.com/inward/record.url?scp=84873623015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873623015&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A3165

DO - 10.3174/ajnr.A3165

M3 - Article

C2 - 22936096

AN - SCOPUS:84873623015

VL - 34

SP - 35

EP - 40

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 1

ER -